Home Slide
EvoRx Technologies | News
EvoRx strives to discover and develop innovative peptide therapeutic and targeted radiopharmaceuticals for treatment and diagnosis of disease with high unmet medical need. It’s proprietary Evo-Link™ technology rapidly generates exceedingly high diversity cyclic peptide libraries. The libraries are screened for drug-like activity in environments that mimic the physiological environment of the body. This results in EvoTides™, uniquely structured peptides that are highly stable in human serum, have antibody-like specificity and affinity, and can be designed to be membrane permeable. These features allow us to target protein interactions previously thought of as “undruggable.”
peptide therapy radiopharmaceuticals protein interaction cyclic peptide libraries
266
page-template-default,page,page-id-266,ajax_fade,page_not_loaded,

EvoRx Meets With Congresswoman Judy Chu and Administrator Maria Contreras-Sweet

Click Here for PDF


AstraZeneca and EvoRx Technologies Announce Successful Completion of Collaboration

Click Here for PDF


Successful completion of our phase I SBIR summarized in AACR poster

Dr. Steven Millward from MD Anderson presents a poster at this year’s American Association for Cancer Research (AACR) national meeting summarizing the successful completion of our phase I SBIR contract. We are continuing to pursue this exciting application of the technology for imagine and therapeutic purposes.


Professor Richard Roberts, founding member of EvoRx Technologies, Inc., named Chair of the Mork Family Department of Chemical Engineering and Materials Science at the University of Southern California

Click Here for Article


EvoRx expands its Pasadena, California operations, now utilizing 3,100 sq. ft of lab and office space

PASADENA, California, November 1, 2014. EvoRx Technologies Inc. has relocated to a larger laboratory suite in the Alexandria Real Estate facility located at 129 North Hill Street in Pasadena, CA.


EvoRx Technologies Inc. is awarded a Phase I SBIR contract from the National Cancer Institute

PASADENA, California, September 20, 2013. EvoRx Technologies, Inc., announced today that the company has been awarded a $249,748 Phase I Small Business Innovation Research (SBIR) contract from the National Cancer Institute (NCI)/National Institutes of Health (NIH). The project, entitled “Novel Imaging Agents to Expand the Clinical Tool Kit for Cancer,” will support the development of a next generation radiopharmaceutical in collaboration with the University of Texas MD Anderson Cancer Center.

“We suspect that our EvoTides will have tumor uptake and systemic clearance properties that are far superior than antibodies for the development of radiopharmaceuticals for therapy and imaging,” said Dr. Stephen Fiacco, CEO of EvoRx. “I’m excited to test our theory.”


Dr. Stephen Fiacco, CEO of EvoRx Technologies, is invited to speak at the Oligonucleotide and Peptide Therapeutics Conference (TIDES)

In a talk titled “Discovery of Membrane Permeable Peptides Able to Hit MicroRNA Targets,” Dr. Fiacco shares data relating to EvoRx’s ability to design drug like peptides able to target pre-mircoRNA and modulate protein expression levels in pancreatic cancer cells.

Click Here for Article


EvoRx Technologies, Inc. is announced as a winner of the 2012 USC Stevens Center for Innovation Ideas Empowered Program

EvoRx Technologies, Inc. was selected as a winner of the USC Stevens Center for Innovation Ideas Empowered Program. The Ideas Empowered Program is designed to bridge the gap between basic research and the marketplace. EvoRx won their award due to their innovative technology and approach to commercialization.

Click Here for Article


EvoRx featured on Forbes.com

Shortly after founding EvoRx Technologies, CEO Dr. Stephen Fiacco sits down with Forbes to share a brief but exciting overview of this new innovative Start-up.

Click Here for Article